Rifaximin Alternatives Compared
| Rifaximin | Stelara (ustekinumab) | Entyvio (vedolizumab) |
|
|---|
| Rifaximin | Stelara (ustekinumab) | Entyvio (vedolizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hepatic Encephalopathy, Irritable Bowel Syndrome with Diarrhea, Irritable Bowel Syndrome, Crohn's Disease, Traveler's Diarrhea, Diarrhea, Diarrhea - Chronic. Rifaximin may also be used... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Crohn's Disease
|
|||||||||||||||
| More about Rifaximin | More about Stelara (ustekinumab) | More about Entyvio (vedolizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Rifaximin has an average rating of 6.6 out of 10 from a total of 155 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 33% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 252 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 15% reported a negative effect. |
Entyvio has an average rating of 6.2 out of 10 from a total of 162 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Rifaximin side effects |
View all Stelara side effects |
View all Entyvio side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Stelara prices |
View all Entyvio prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Xifaxan | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
10.19 hours |
1291.2 hours |
600 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 89 drugs are known to interact with Rifaximin:
|
A total of 535 drugs are known to interact with Stelara:
|
A total of 163 drugs are known to interact with Entyvio:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 25, 2004 |
September 25, 2009 |
May 20, 2014 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.